Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Questions about gemcitabine dose rate: answered or unanswered?

× No keyword cloud information.

5 in total

1. Gemcitabine, fludarabine and melphalan as a reduced-intensity conditioning regimen for allogeneic stem cell transplant in relapsed and refractory Hodgkin lymphoma: preliminary results.

Authors: Paolo Anderlini; Rima M Saliba; Celina Ledesma; Christina Chancoco; Amin M Alousi; Elizabeth J Shpall; Uday R Popat; Chitra M Hosing; Issa F Khouri; Yago Nieto; Stefan Ciurea; Anas Younes; Michelle A Fanale; Sandra Acholonu; Rosamar Valverde; Richard E Champlin
Journal: Leuk Lymphoma Date: 2011-10-24

Review 2. Intraperitoneal gemcitabine chemotherapy is safe for patients with resected pancreatic cancer: final clinical and pharmacologic data from a phase II protocol and recommended future directions.

Authors: Paul H Sugarbaker; O Anthony Stuart
Journal: J Gastrointest Oncol Date: 2021-04

Review 3. Improving gemcitabine-mediated radiosensitization using molecularly targeted therapy: a review.

Authors: Meredith A Morgan; Leslie A Parsels; Jonathan Maybaum; Theodore S Lawrence
Journal: Clin Cancer Res Date: 2008-11-01 Impact factor: 12.531

4. Pharmacokinetics of gemcitabine at fixed-dose rate infusion in patients with normal and impaired hepatic function.

Authors: Alessandra Felici; Susanna Di Segni; Michele Milella; Simona Colantonio; Isabella Sperduti; Barbara Nuvoli; Michela Contestabile; Andrea Sacconi; Massimo Zaratti; Gennaro Citro; Francesco Cognetti
Journal: Clin Pharmacokinet Date: 2009 Impact factor: 6.447

5. Intraperitoneal gemcitabine chemotherapy treatment for patients with resected pancreatic cancer: rationale and report of early data.

Authors: Paul H Sugarbaker; O Anthony Stuart; Lana Bijelic
Journal: Int J Surg Oncol Date: 2011-12-12

5 in total